AstraZeneca is buying Fusion Pharmaceuticals, a Canadian company specializing in radioconjugation cancer treatments, for $2.4 billion.
Petru Nicolaescu
Health
Unsplash.com
Always see our news on Google
The acquisition of Fusion Pharmaceuticals by AstraZeneca brings innovative new treatments to the company's portfolio. Radioconjugates developed by Fusion are an alternative to chemotherapy and radiotherapy, minimizing damage to healthy cells. The most advanced treatment, FPI-2265, is for patients with metastatic prostate cancer.
Latest News
21:13
Police officers in Galați seized 35 luxury cars, valued at 2.8 million euros, in a money laundering investigation
20:59
Donald Trump proposes Dana White, the head of the UFC, for the position of White House press secretary
20:47
Valentin Mihăilă and Nicolae Stanciu miss the Nations League matches / Rareș Ilie called up urgently
20:30
George Simion accuses Poland’s interior minister of spreading false information about the attacker in Kraków
20:21
An 18-year-old motorcyclist suffered severe burns after his motorcycle caught fire following a collision with a bus
See more news
NEWS ON THE SAME TOPICS
IT&C knowledge
Novo collaborates with Anthropic to use artificial intelligence in the research and development of new medicines
International
An experimental cancer vaccine, developed by Moderna and Merck, has shown promising results in patients with melanoma.
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
